Badal Raval, MD
Nephrology · Fort Wayne, INNPI 1427009653
Payments from drug & device makers
Across 135 payments — averaging $19.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Akebia Therapeutics Inc$543
- AstraZeneca$391
- Fresenius USA Marketing, Inc.$215
- Otsuka America Pharmaceutical, Inc.$198
- Bayer$192
- Vifor Pharma, Inc.$189
- plus $860 from 14 others
What the payments were for
- Food & beverage$2,51597%
- Education$713%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Akebia Therapeutics Inc | 37 | $543 |
| AstraZeneca(2 entities) | 20 | $391 |
| Fresenius USA Marketing, Inc. | 11 | $215 |
| Otsuka America Pharmaceutical, Inc. | 8 | $198 |
| Bayer | 10 | $192 |
| Vifor Pharma, Inc. | 8 | $189 |
| Travere Therapeutics, Inc. | 6 | $151 |
| Amgen(2 entities) | 8 | $124 |
| Mallinckrodt Hospital Products Inc. | 5 | $102 |
| Bard Peripheral Vascular, Inc. | 1 | $101 |
| OPKO Pharmaceuticals, LLC | 5 | $94 |
| Novartis | 3 | $58 |
| Boehringer Ingelheim | 3 | $49 |
| Aurinia Pharma U.S., Inc. | 2 | $38 |
| Lexicon Pharmaceuticals, Inc. | 2 | $35 |
| GSK | 2 | $29 |
| Calliditas Therapeutics US Inc. | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Mallinckrodt Enterprises LLC | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
How this compares
$2,587 in reported general payments places this provider in the 65th percentile of 238 nephrology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sevelamer Carbonate | 27 | $7,707 |
| Torsemide | 26 | $636 |
| Hydralazine Hcl | 29 | $531 |
| Calcitriol | 36 | $512 |
| Losartan Potassium | 56 | $290 |
| Furosemide | 67 | $281 |
| Lisinopril | 28 | $255 |
| Bumetanide | 15 | $251 |
| Amlodipine Besylate | 52 | $169 |
| Carvedilol | 14 | $156 |
| Tamsulosin Hcl | 19 | $114 |
| Hydrochlorothiazide | 23 | $64 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Fort Wayne
- Andrew OshaughnessyFort Wayne$1.2M
- Garima GuptaFort Wayne$666K
- John DuckerFort Wayne$135K
- Melanie BarridoFort Wayne$66K
- Irfan MunirFort Wayne$5K
- Sajjad HabibFort Wayne$4K
- Kanakapura VenkatakrishnaFort Wayne$4K
- Rajiv AgarwalIndianapolis$1.2M
- Jay WishIndianapolis$502K
- Bruce MolitorisIndianapolis$471K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.